Monocyte activation

Across TCGA pan-cancer cohorts, RNA activity of the Monocyte activation pathway differs between tumor and matched normal tissue in 11 of the 18 cancer types tested.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KIRC and KICH, show the opposite pattern, with lower activity in tumor tissue.

KIRC, KICH, and KIRP show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
KIRC	All	II,III,IV	−0.039	<.001	10	view →
KICH	All	III,IV	−0.104	<.001	9	view →
KIRP	Female	All	−0.096	<.001	9	view →
STAD	Male	II,III,IV	+0.079	.001	4	view →
LUSC	All	II,III,IV	−0.056	<.001	4	view →
READ	Female	All	−0.120	.002	2	view →
BLCA	Male	IV	−0.097	.019	2	view →
PRAD	All	All	−0.036	<.001	2	view →
COAD	All	All	−0.025	.034	2	view →
HNSC	Female	IV	+0.070	.046	1	view →
LIHC	Male	II,III,IV	+0.037	.030	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 11 strongest of 11 lineages.

GO:0042117–KIRC

Open the KIRC breakdown →